| 1 |
Sintering of fat crystal networks in oil during post‐crystallization processes
Dorota Johansson, Björn Bergenståhl · Journal of the American Oil Chemists Society
|
Aug 1995 |
122 |
| 2 |
Wetting of fat crystals by triglyceride oil and water. 1. The effect of additives
Dorota Johansson, Björn Bergenståhl, Eva Lundgren · Journal of the American Oil Chemists Society
|
Aug 1995 |
72 |
| 3 |
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial
Göran Tornling, Rohit Batta, Joanna C. Porter et al. · EClinicalMedicine
Open access |
25 Oct 2021 |
48 |
| 4 |
Water‐in‐triglyceride oil emulsions. Effect of fat crystals on stability
Dorota Johansson, Björn Bergenståhl, Eva Lundgren · Journal of the American Oil Chemists Society
|
Aug 1995 |
41 |
| 5 |
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome
Ilse C. Schrieks, Anna Nozza, Barbara Elisabeth Stähli et al. · Diabetes Care
Open access |
14 Jun 2018 |
40 |
| 6 |
Histopathological Studies on Kidneys from Patients Treated with Large
John Falk, Gert Lindblad, Beatrice Westman · Transfusion
|
Nov 1972 |
39 |
| 7 |
A Novel Polypeptide Derived From Human Lactoferrin in Sodium Hyaluronate Prevents Postsurgical Adhesion Formation in the Rat
Elin Nilsson, Camilla Björn, Veronika Sjöstrand et al. · Annals of Surgery
|
23 Nov 2009 |
32 |
| 8 |
A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s
Ariane L. Herrick, Rohit Batta, Kamilla Overbeck et al. · Lara D. Veeken
Open access |
27 Jul 2022 |
19 |
| 9 |
Weak gels of fat crystals in oils at low temperatures and their fractal nature
Dorota Johansson · Journal of the American Oil Chemists Society
|
Oct 1995 |
16 |
| 10 |
The influence of temperature on interactions and structures in semisolid fats
Dorota Johansson · Journal of the American Oil Chemists Society
|
Oct 1995 |
15 |
| 11 |
[PP.02.17] SUCCESSFUL COMPLETION OF A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE TRIAL FOR THE FIRST IN CLASS ANGIOTENSIN AT2-RECEPTOR AGONIST COMPOUND 21
U. Muscha Steckelings, Lena G.E. Mårtensson Lindblad, Anna Leisvuori et al. · Journal of Hypertension
|
30 Jul 2017 |
14 |
| 12 |
Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats
Göran Tornling, Rohit Batta, Dan Salvail et al. · International Journal of Molecular Sciences
Open access |
19 Apr 2023 |
13 |
| 13 |
Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study
Eva Lesén, Daniel Granfeldt, Anthony Berthon et al. · Journal of Cancer
Open access |
2019 |
12 |
| 14 |
Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome
Barbara Elisabeth Stähli, Anna Nozza, Ilse C. Schrieks et al. · The Journal of Clinical Endocrinology & Metabolism
Open access |
6 Apr 2018 |
12 |
| 15 |
A digital therapy targeting anxiety in pulmonary fibrosis: A decentralized randomized controlled trial
Joshua J. Solomon, Robert W. Hallowell, Cecilia Ganslandt et al. · Respirology
Open access |
3 Dec 2024 |
9 |
| 16 |
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
Göran Tornling, Rohit Batta, Joanna C. Porter et al. · medRxiv
PreprintOpen access |
28 Jan 2021 |
9 |
| 17 |
Stoma Care Nurse Consultations Regarding Leakages and Peristomal Skin Complications During the First Year After Ostomy Creation: A Chart Review
Eva I. Persson, Annabelle Forsmark, Gina Scheffel et al. · International Wound Journal
Open access |
Apr 2025 |
6 |
| 18 |
Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist
Erik Rein‐Hedin, Folke Sjöberg, Cecilia Ganslandt et al. · Clinical and Translational Science
Open access |
Feb 2024 |
4 |
| 19 |
Respiratory Nurse Leadership Requires Increased Profile, Role Clarity and Stronger Career Pathways: Binational Delphi Consensus Process and TSANZ Position Statement
Rebecca T. Disler, Catherine Buchan, Nikola Ncube et al. · Respirology
Open access |
4 Jul 2025 |
1 |
| 20 |
A110-06 Buloxibutid Stabilizes and Improves Lung Function in Idiopathic Pulmonary Fibrosis and Elevates Plasma Mmp-13, Linking AT2 Receptor Activation in Alveolar Epithelial Type 2 Cells to Resolution of Fibrosis
J Raud, A Mousa, K Von Wachenfeldt et al. · American Journal of Respiratory and Critical Care Medicine
|
May 2026 |
0 |
| 21 |
C103-23 Buloxibutid’s Efficacy in the Phase 2a Air IPF Trial: Comparative Analysis of Baseline Characteristics of Indian Versus World Cohorts
K R Kirov, M Thillai, B Van Den Blink et al. · American Journal of Respiratory and Critical Care Medicine
|
May 2026 |
0 |
| 22 |
D109-02 Microvascular Normalization and Fibrosis Regression by The Angiotensin II Type 2 Receptor Agonist Buloxibutid in Pulmonary Hypertension Associated With Interstitial Lung Disease
J Raud, J Hofman, D Salvail et al. · American Journal of Respiratory and Critical Care Medicine
|
May 2026 |
0 |
| 23 |
Beneficial effects of the AT 2 receptor agonist buloxibutid (C21) against acute alveolar epithelial cell inflammation during antiviral responses
Franco Conforti, Joseph Bell, Robert A. Ridley et al. · ERJ Open Research
Open access |
22 Jan 2026 |
0 |
| 24 |
#3252 Anti-fibrotic profile of a next-generation AT2 receptor agonist in human fibrotic kidney tissue
Johanna Gräns, Jimmie Hofman, Johan Raud · Nephrology Dialysis Transplantation
|
Oct 2025 |
0 |
| 25 |
Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19
Rohit Batta, Göran Tornling, E. Rosendahl et al. · European Heart Journal
Open access |
Oct 2022 |
0 |
| 26 |
Seven Days Treatment With the Angiotensin II Type 2 Receptor Agonist C21 in Hospitalized COVID-19 Patients: A Placebo-Controlled Randomized Phase 2 Trial
Göran Tornling, Rohit Batta, Joanna C. Porter et al. · SSRN Electronic Journal
PreprintOpen access |
2021 |
0 |